The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Targeting the mTOR Signaling Network for Cancer Therapy
Open accessAbstract
The serine-threonine kinase mammalian target of rapamycin (mTOR) plays a major role in the regulation of protein translation, cell growth, and metabolism. Alterations of the mTOR signaling pathway are common in cancer, and thus mTOR is being actively pursued as a therapeutic target. Rapamycin and its analogs (rapalogs) have proven effective as anticancer agents in a broad range of preclinical models. Clinical trials using rapalogs have demonstrated important clinical benefits in several cancer types; however, objective response rates achieved with single-agent therapy have been modest. Rapalogs may be more effective in combination with other anticancer agents, including chemotherapy and targeted therapies. It is increasingly apparent that the mTOR signaling network is quite complex, and rapamycin treatment leads to different signaling responses in different cell types. A better understanding of mTOR signaling, the mechanism of action of rapamycin, and the identification of biomarkers of response will lead to more optimal targeting of this pathway for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Shi, Y., Yan, H., Frost, P., Gera, J., & Lichtenstein, A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0068 · Cited by 368
RetractedTOR signaling in growth and metabolism
Wullschleger, S., Loewith, R., & Hall, M. N. (2006) · Cell · doi:10.1016/j.cell.2006.01.016 · Cited by 5,787
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Liaw, D., Marsh, D. J., Li, J., Dahia, P. L. M., Wang, S. I., Zheng, Z., Bose, S., Call, K. M., Tsou, H. C., Peacoke, M., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-64 · Cited by 2,091
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J., & Cantley, L. C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00568-3 · Cited by 1,555
Regulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545
Jacinto, E., Facchinetti, V., Liu, D., Soto, N., Wei, S., Jung, S. Y., Huang, Q., Qin, J., & Su, B. (2006) · Cell · doi:10.1016/j.cell.2006.08.033 · Cited by 1,410
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism
Gingras, A.-C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., & Sonenberg, N. (1999) · Genes & Development · doi:10.1101/gad.13.11.1422 · Cited by 1,343
Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
Bissler, J. J., McCormack, F. X., Young, L. R., Elwing, J. M., Chuck, G., Leonard, J. M., Schmithorst, V. J., Laor, T., Brody, A. S., Bean, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa063564 · Cited by 1,253
The LKB1 tumor suppressor negatively regulates mTOR signaling
Shaw, R. J., Bardeesy, N., Manning, B. D., Lopez, L., Kosmatka, M., DePinho, R. A., & Cantley, L. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.007 · Cited by 1,077
An integrative genomic and proteomic analysis of pik3ca, pten, and akt mutations in breast cancer.
Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W.-L., Davies, M., Carey, M., Hu, Z., Guan, Y., Sahin, A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6854 · Cited by 1,054
Self-citationSirolimus for Kaposi's Sarcoma in Renal-Transplant Recipients
Stallone, G., Schena, A., Infante, B., Di Paolo, S., Loverre, A., Maggio, G., Ranieri, E., Gesualdo, L., Schena, F. P., & Grandaliano, G. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042831 · Cited by 990
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Akt regulates growth by directly phosphorylating Tsc2
Potter, C. J., Pedraza, L. G., & Xu, T. (2002) · Nature Cell Biology · doi:10.1038/ncb840 · Cited by 959
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933
Nobukuni, T., Joaquin, M., Roccio, M., Dann, S. G., Kim, S. Y., Gulati, P., Byfield, M. P., Backer, J. M., Natt, F., Bos, J. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506925102 · Cited by 757
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
Wan, X., Harkavy, B., Shen, N., Grohar, P., & Helman, L. J. (2007) · Oncogene · doi:10.1038/sj.onc.1209990 · Cited by 755
Roux, P. P., Ballif, B. A., Anjum, R., Gygi, S. P., & Blenis, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405659101 · Cited by 750
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s
Frias, M. A., Thoreen, C. C., Jaffe, J. D., Schroder, W., Sculley, T., Carr, S. A., & Sabatini, D. M. (2006) · Current Biology · doi:10.1016/j.cub.2006.08.001 · Cited by 695
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Yao, J. C., Phan, A. T., Chang, D. Z., Wolff, R. A., Hess, K., Gupta, S., Jacobs, C., Mares, J. E., Landgraf, A. N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7858 · Cited by 649
Self-citationHess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.7977 · Cited by 641
mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes
Hresko, R. C., & Mueckler, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508361200 · Cited by 635
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer
Thomas, G. V., Tran, C., Mellinghoff, I. K., Welsbie, D. S., Chan, E., Fueger, B., Czernin, J., & Sawyers, C. L. (2006) · Nature Medicine · doi:10.1038/nm1337 · Cited by 604
The NF1 tumor suppressor critically regulates TSC2 and mTOR
Johannessen, C. M., Reczek, E. E., James, M. F., Brems, H., Legius, E., & Cichowski, K. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503224102 · Cited by 601
Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., Hsueh, T., Chen, Y., Wang, W., Youngkin, D., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050008 · Cited by 593
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Yang, Q., Inoki, K., Ikenoue, T., & Guan, K.-L. (2006) · Genes & Development · doi:10.1101/gad.1461206 · Cited by 517
Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma
Witzig, T. E., Geyer, S. M., Ghobrial, I., Inwards, D. J., Fonseca, R., Kurtin, P., Ansell, S. M., Luyun, R., Flynn, P. J., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.466 · Cited by 514
Beuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.0988 · Cited by 479
Tabernero, J., Rojo, F., Calvo, E., Burris, H., Judson, I., Hazell, K., Martinelli, E., Cajal, S. R. Y., Jones, S., Vidal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5482 · Cited by 474
Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases
Raught, B., Peiretti, F., Gingras, A., Livingstone, M., Shahbazian, D., Mayeur, G. L., Polakiewicz, R. D., Sonenberg, N., & Hershey, J. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600193 · Cited by 473
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
Identification of Protor as a novel Rictor-binding component of mTOR complex-2
Pearce, L. R., Huang, X., Boudeau, J., Pawłowski, R., Wullschleger, S., Deak, M., Ibrahim, A. F. M., Gourlay, R., Magnuson, M. A., & Alessi, D. R. (2007) · Biochemical Journal · doi:10.1042/bj20070540 · Cited by 464
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
Yu, K., Toral-Barza, L., Discafani, C., Zhang, W. G., Skotnicki, J., Frost, P., & Gibbons, J. J. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080249 · Cited by 420
Cancer-specific mutations in PIK3CA are oncogenic in vivo
Bader, A. G., Kang, S., & Vogt, P. K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510857103 · Cited by 420
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
and members of the Southeast Sweden Breast Cancer Group, Pérez-Tenorio, G., & Stål, O. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600126 · Cited by 394
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Graff, J. R., Konicek, B. W., Vincent, T. M., Lynch, R. L., Monteith, D., Weir, S. N., Schwier, P., Capen, A., Goode, R. L., Dowless, M. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32044 · Cited by 380
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C.-T., Miller, S. A., Yu, Z., Xia, W., Lin, S.-Y., & Hung, M.-C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zeng, Z., Sarbassov, D. D., Samudio, I. J., Yee, K. W. L., Munsell, M. F., Ellen Jackson, C., Giles, F. J., Sabatini, D. M., Andreeff, M., & Konopleva, M. (2007) · Blood · doi:10.1182/blood-2006-06-030833 · Cited by 342
Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivières, S., Mercep, L., & Ferrari, S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14424 · Cited by 342
Gera, J. F., Mellinghoff, I. K., Shi, Y., Rettig, M. B., Tran, C., Hsu, J.-H., Sawyers, C. L., & Lichtenstein, A. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309999200 · Cited by 331
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Self-citationBoulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
Duran, I., Kortmansky, J., Singh, D., Hirte, H., Kocha, W., Goss, G., Le, L., Oza, A., Nicklee, T., Ho, J., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603419 · Cited by 317
Determinants of Rapamycin Sensitivity in Breast Cancer Cells
Noh, W.-C., Mondesire, W. H., Peng, J., Jian, W., Zhang, H., Dong, J., Mills, G. B., Hung, M.-C., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0043 · Cited by 285
Self-citationYee, K. W. L., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0764 · Cited by 285
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 279
Barlund, M., Forozan, F., Kononen, J., Bubendorf, L., Chen, Y., Bittner, M. L., Torhorst, J., Haas, P., Bucher, C., Sauter, G., et al. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1252 · Cited by 275
Raught, B. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.434 · Cited by 270
Geoerger, B., Kerr, K., Tang, C. B., Fung, K., Powell, B., Sutton, L. N., Phillips∥, P. C., & Janss, A. J. (2001) · PubMed · Cited by 261
mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation
Hong, F., Larrea, M. D., Doughty, C., Kwiatkowski, D. J., Squillace, R., & Slingerland, J. M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.027 · Cited by 260
Jastrzebski, K., Hannan, K. M., Tchoubrieva, E. B., Hannan, R. D., & Pearson, R. B. (2007) · Growth Factors · doi:10.1080/08977190701779101 · Cited by 240
Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Dudkin, L., Dilling, M. B., Cheshire, P. J., Harwood, F. C., Hollingshead, M. G., Arbuck, S. G., Travis, R., Sausville, E. A., & Houghton, P. J. (2001) · PubMed · Cited by 232
Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779.
Shi, Y., Gera, J., Hu, L., Hsu, J.-H., Bookstein, R., Li, W., & Lichtenstein, A. K. (2002) · PubMed · Cited by 231
CCI‐779 in metastatic melanoma: A Phase II trial of the California Cancer Consortium
Margolin, K., Longmate, J., Baratta, T., Synold, T., Christensen, S., Weber, J., Gajewski, T., Quirt, I., & Doroshow, J. H. (2005) · Cancer · doi:10.1002/cncr.21265 · Cited by 227
Rictor and Integrin-Linked Kinase Interact and Regulate Akt Phosphorylation and Cancer Cell Survival
McDonald, P. C., Oloumi, A., Mills, J., Dobreva, I., Maidan, M., Gray, V., Wederell, E. D., Bally, M. B., Foster, L. J., & Dedhar, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5869 · Cited by 224
Rizzieri, D. A., Feldman, E., DiPersio, J. F., Gabrail, N., Stock, W., Strair, R., Rivera, V. M., Albitar, M., Bedrosian, C. L., & Giles, F. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1372 · Cited by 222
Huang, S., Shu, L., Dilling, M. B., Easton, J., Harwood, F. C., Ichijo, H., & Houghton, P. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00180-1 · Cited by 216
Hidalgo, M., Buckner, J. C., Erlichman, C., Pollack, M. S., Boni, J. P., Dukart, G., Marshall, B., Speicher, L., Moore, L., & Rowinsky, E. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0118 · Cited by 212
Tanaka, C., O’Reilly, T., Kovarik, J. M., Shand, N., Hazell, K., Judson, I., Raymond, E., Zumstein-Mecker, S., Stephan, C., Boulay, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1127 · Cited by 211
eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3′UTR
Culjkovic, B., Topisirovic, I., Skrabanek, L., Ruiz-Gutierrez, M., & Borden, K. L. B. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501019 · Cited by 204
Ansell, S. M., Inwards, D. J., Rowland, K. M., Flynn, P. J., Morton, R. F., Moore, D. F., Kaufmann, S. H., Ghobrial, I., Kurtin, P. J., Maurer, M., et al. (2008) · Cancer · doi:10.1002/cncr.23580 · Cited by 203
Integrin (α6β4) regulation of eIF-4E activity and VEGF translation
Chung, J., Bachelder, R. E., Lipscomb, E. A., Shaw, L. M., & Mercurio, A. M. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112015 · Cited by 202
Lu, C.-H., Wyszomierski, S. L., Tseng, L.-M., Sun, M.-H., Lan, K.-H., Neal, C. L., Mills, G. B., Hortobagyi, G. N., Esteva, F. J., & Yu, D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2837 · Cited by 200
Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba, J. M., deGraffenried, L. A., Friedrichs, W. E., Fulcher, L. C., Grünwald, V., Weiss, G. R., & Hidalgo, M. M. (2003) · PubMed · Cited by 191
eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy
Ramírez-Valle, F., Braunstein, S., Zavadil, J., Formenti, S. C., & Schneider, R. J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710215 · Cited by 191
Wang, L., Harris, T. E., & Lawrence, J. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800723200 · Cited by 186
Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., Youmans, A., Polivy, A., Mandato, L., McDermott, D., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.020 · Cited by 178
deGraffenried, L. A., Fulcher, L., Friedrichs, W. E., Grünwald, V., Ray, R. B., & Hidalgo, M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh388 · Cited by 177
Steelman, L. S., Navolanic, P. M., Sokolosky, M. L., Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Wong, E. W. T., Stadelman, K. M., Terrian, D. M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.49 · Cited by 170
Stability of Phosphoprotein as a Biological Marker of Tumor Signaling
Baker, A. F., Dragovich, T., Ihle, N. T., Williams, R., Fenoglio-Preiser, C., & Powis, G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0422 · Cited by 170
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling
Beeram, M., Tan, Q.-T. N., Tekmal, R. R., Russell, D., Middleton, A., & deGraffenried, L. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm170 · Cited by 170
P-Rex1 Links Mammalian Target of Rapamycin Signaling to Rac Activation and Cell Migration
Hernández-Negrete, I., Carretero-Ortega, J., Rosenfeldt, H., Hernández-Garciía, R., Calderón-Salinas, J. V., Reyes-Cruz, G., Gutkind, J. S., & Vázquez-Prado, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703771200 · Cited by 161
Moreno, A. C., Akçakanat, A., Munsell, M. F., Soni, A., Yao, J. C., & Meric‐Bernstam, F. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0202 · Cited by 157
Self-citationAwada, A. H., Cardoso, F., Fontaine, C., Dirix, L. Y., Grève, J. D., Sotiriou, C. P., Steinseifer, J., Wouters, C., Tanaka, C., Zoellner, U., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.003 · Cited by 155
Pandya, K. J., Dahlberg, S. E., Hidalgo, M. M., Cohen, R. B., Lee, M. W., Schiller, J. H., & Johnson, D. H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318155a439 · Cited by 148
Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy
Iwenofu, O. H., Lackman, R. D., Staddon, A. P., Goodwin, D. G., Haupt, H. M., & Brooks, J. S. (2007) · Modern Pathology · doi:10.1038/modpathol.3800995 · Cited by 137
Shor, B., Zhang, W., Toral‐Barza, L., Lucas, J., Abraham, R. T., Gibbons, J. J., & Yu, K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6487 · Cited by 131
Antitumoral Activity of Rapamycin in Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Wienecke, R., Fackler, I., Linsenmaier, U., Mayer, K., Licht, T., & Kretzler, M. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.05.018 · Cited by 118
Role of Glycogen Synthase Kinase 3β in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity
Dong, J., Peng, J., Zhang, H., Mondesire, W. H., Jian, W., Mills, G. B., Hung, M., & Meric‐Bernstam, F. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2501 · Cited by 111
Self-citationeIF4E knockdown decreases breast cancer cell growth without activating Akt signaling
Soni, A., Akçakanat, A., Singh, G., Luyimbazi, D. T., Zheng, Y., Kim, D., Gonzalez-Angulo, A. M., & Meric‐Bernstam, F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2357 · Cited by 107
Self-citationA phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
Colombo, N., McMeekin, S., Schwartz, P. E., Kostka, J., Sessa, C., Gehrig, P. A., Holloway, R., Braly, P. S., Matei, D. E., & Einstein, M. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5516 · Cited by 100
Determinants of RASistance to Anti–Epidermal Growth Factor Receptor Agents
Baselga, J. M., & Rosen, N. X. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.3700 · Cited by 87
Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway
Bermúdez, O. M., Marchetti, S., Pagès, G., & Gimond, C. (2008) · Oncogene · doi:10.1038/sj.onc.1211040 · Cited by 86
Liu, W., Su, H. C., Hildebrandt, I. J., Phelps, M. E., Czernin, J. G., & Weber, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1824 · Cited by 82
Hsp70 associates with Rictor and is required for mTORC2 formation and activity
Martin, J., Masri, J., Bernath, A., Nishimura, R. N., & Gera, J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.086 · Cited by 79
Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex
Herry, I., Neukirch, C., Debray, M., Mignon, F., & Crestani, B. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.07.017 · Cited by 75
Chawla, S. P., Tolcher, A. W., Staddon, A. P., Schuetze, S. M., D’Amato, G. Z., Blay, J., Sankhala, K. K., Daly, S. T., Rivera, V. M., & Demetri, G. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.9505 · Cited by 74
Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected
Stoeltzing, O., Meric‐Bernstam, F., & Ellis, L. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.013 · Cited by 67
Self-citationComparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases
Akçakanat, A., Şahin, A. A., Shaye, A. N., Velasco, M. A. D., & Meric‐Bernstam, F. (2008) · Cancer · doi:10.1002/cncr.23456 · Cited by 66
Self-citationLaw, M. E., Forrester, E., Chytil, A., Corsino, P. E., Green, G., Davis, B. J., Rowe, T. C., & Law, B. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1672 · Cited by 66
S6K1 Plays a Key Role in Glial Transformation
Nakamura, J. L., Garcia, E., & Pieper, R. O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6188 · Cited by 66
Rapamycin regulates the phosphorylation of rictor
Akçakanat, A., Singh, G., Hung, M., & Meric‐Bernstam, F. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.151 · Cited by 63
Self-citationAndré, F., Broglio, K. R., Roche, H. H., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9146 · Cited by 59
Slomovitz, B. M., Lu, K. H., Johnston, T., Munsell, M. A., Ramondetta, L. M., Broaddus, R. R., Coleman, R. L., Walker, C., Gershenson, D. M., Burke, T. W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5502 · Cited by 39
Sadler, T., Gavriil, M., Annable, T., Frost, P., Greenberger, L. M., & Zhang, Y. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01170 · Cited by 38
Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
Smith, S. M., Pro, B., Cisneros, A., Smith, S. E., Stiff, P. J., Lester, E. P., Modi, S., Dancey, J. E., Vokes, E. E., & van Besien, K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8514 · Cited by 33
Hess, G., Romaguera, J. E., Verhoef, G. E. G., Herbrecht, R., Crump, M., Strahs, A. L., Clancy, J. S., Hewes, B., & Coiffier, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8513 · Cited by 27
Baselga, J. M., van Dam, P. A., Greil, R., Gardner, H., Bandaru, R., Molloy, B., Steinseifer, J., Phillips, P., Dixon, J. M., & Rugo, H. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.530 · Cited by 23
Cited by
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks
Alers, S., Löffler, A. S., Wesselborg, S., & Stork, B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06159-11 · Cited by 1,483
“However, although mTOR signaling is frequently dysregulated in cancer, rapamycin analogs do not show any considerable activity as single agents in many tumor types and thus are often used in combination therapy (79).”
BackgroundThe PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
The Role of Autophagy in Cancer: Therapeutic Implications
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0047 · Cited by 1,215
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160
Metadata
- Authors
- Meric-Bernstam, F., & Gonzalez-Angulo, A. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-05-01
- Volume
- 27
- Issue
- 13
- Pages
- 2278-2287
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2071394735
- Cited by
- 639
- References
- 116
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.